Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
SGMO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $3.18
Previous CloseN/A
Volume2.84M
Average Volume (3M)4.07M
Market Cap
$207.87M
Enterprise Value$174.15M
Total Cash (Recent Filing)$140.42M
Total Debt (Recent Filing)$27.69M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Mar 17, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding208,646,870
10 Day Avg. Volume4,469,055
30 Day Avg. Volume4,074,146
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.98
Price to Cash Flow (P/CF)4.40
P/FCF Ratio4.50
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.84
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$5.80Price Target Upside491.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
PartnershipsSGMO continues to advance discussions regarding a potential collaboration agreement around the study data.
Regulatory ApprovalFDA agreed that the eGFR slope at 52 weeks can serve as an intermediate endpoint for potential accelerated approval.
Bears Say
Partnership TerminationPfizer has indicated to Sangamo that the termination of their collaboration reflects its decision not to proceed with the Biologics License Application and Marketing Authorization Application.
---
Ownership Overview
2.46% Insiders
16.44% Mutual Funds
7.24% Other Institutional Investors
66.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.30 and its highest was $3.18 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Sangamo Biosciences’s market cap is $207.87M.
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Mar 17, 2025 which is in 2 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on Nov 12, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.015 by $0.055.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -0.09.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 208,646,870 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.015. Following the earnings report the stock price went down -9.963%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Currently, no hedge funds are holding shares in SGMO
---
Sangamo Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (491.84% Upside)
$5.80 (491.84% Upside)
Blogger Sentiment
Bullish
SGMO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 63.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.57%
12-Months-Change
Fundamentals
Return on Equity
-156.42%
Trailing 12-Months
Asset Growth
-49.36%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Biosciences, now known as Sangamo Therapeutics, Inc., is a biotechnology company focused on developing genomic medicines leveraging its proprietary technology platforms in gene therapy, cell therapy, and genome editing. The company operates primarily in the healthcare and life sciences sectors, working on creating transformative therapies for patients with serious genetic diseases and other unmet medical needs. Sangamo's core products and services revolve around the development of therapeutics for conditions like hemophilia, sickle cell disease, and lysosomal storage disorders.
---
SGMO Company Deck
---
SGMO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was positive, highlighting significant regulatory and clinical advancements, as well as strategic partnerships, despite the financial constraints posed by a limited cash runway.Read More>---
SGMO Stock 12 Month Forecast
Average Price Target
$5.80
▲(491.84% Upside)
Technical Analysis
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering SGMO
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
+32.72%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +32.72% per trade.
---